{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:17:59Z","timestamp":1777493879878,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To investigate the relationship between plasma aripiprazole (ARI) and its metabolite dehydroaripiprazole (DARI) concentrations and prolactin (PRL) levels in Chinese children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective cross-sectional study and the data were collected at Beijing HuiLongGuan Hospital, a Beijing City owned psychiatric hospital, between January 1 and December 31, 2021. Fifty-two child and adolescent inpatients (17 males, 35 females) aged 13\u201318 years and received ARI regardless of diagnosis were included. The steady-state ARI and DARI plasma concentrations were measured using high-performance liquid chromatography-tandem mass spectrometry. The serum PRL levels were measured by chemiluminescence immunoassay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The plasma concentrations of ARI, DARI, and the total of ARI and DARI were negatively correlated with serum PRL levels in female children and adolescents. Approximately 15% of child and adolescent inpatients treated with ARI exhibited subnormal PRL serum levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The results suggest that in addition to regularly monitoring PRL levels, therapeutic drug monitoring for ARI and its main metabolite DARI can help to mitigate the adverse medical consequences associated with PRL reduction. Thus, clinicians should consider the ARI-induced reduction of PRL levels when prescribing ARI to child and adolescent patients, particularly among females.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2022.0068","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T15:28:51Z","timestamp":1675351731000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents"],"prefix":"10.1177","volume":"33","author":[{"given":"Botao","family":"Ma","sequence":"first","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhen","family":"Fan","sequence":"additional","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun","family":"Yun","sequence":"additional","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Qi","sequence":"additional","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4749-9430","authenticated-orcid":false,"given":"Huimei","family":"An","sequence":"additional","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[{"name":"Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.22.6.0451"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2012.03.002"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2010.02156.x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2015.04.011"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2020.0014"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.01.046"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-020-02253-4"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","unstructured":"Findling RL Kauffman R Sallee FR et al. An open-label study of aripiprazole: Pharmacokinetics tolerability and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 2009a;19(4):431\u2013439; doi: 10.1089\/cap.2008.0111","DOI":"10.1089\/cap.2008.0111"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","unstructured":"Findling RL Kauffman RE Sallee FR et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label dose-escalation study. J Clin Psychopharmacol 2008a;28(4):441\u2013446; doi: 10.1097\/JCP.0b013e31817dd520","DOI":"10.1097\/JCP.0b013e31817dd520"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","unstructured":"Findling RL Nyilas M Forbes RA et al. Acute treatment of pediatric bipolar I disorder manic or mixed episode with aripiprazole: A randomized double-blind placebo-controlled study. J Clin Psychiatry 2009b;70(10):1441\u20131451; doi: 10.4088\/JCP.09m05164yel","DOI":"10.4088\/JCP.09m05164yel"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","unstructured":"Findling RL Robb A Nyilas M et al. A multiple-center randomized double-blind placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008b;165(11):1432\u20131441; doi: 10.1176\/appi.ajp.2008.07061035","DOI":"10.1176\/appi.ajp.2008.07061035"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1023\/b:bebm.0000042707.46061.5d"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/01485018908986849"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10401230490487007"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116492"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.03.002"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070179"},{"key":"e_1_3_4_19_1","first-page":"56","article-title":"Prolactin secretion and the immune system","volume":"101","author":"Luca IC.","year":"1997","unstructured":"Luca IC. Prolactin secretion and the immune system. Rev Med Chir Soc Med Natur Iasi, 1997; 101(3\u20134):56\u201359.","journal-title":"Rev Med Chir Soc Med Natur Iasi"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000639"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0092"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000760"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.115.001248"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0062"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000527"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001158"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","unstructured":"Tasaki M Yasui-Furukori N Kubo K et al. Relationship of prolactin concentrations to steady-state plasma concentrations of aripiprazole in patients with schizophrenia. Ther Drug Monit 2021a;43(4):589\u2013592; doi: 10.1097\/FTD.0000000000000843","DOI":"10.1097\/FTD.0000000000000843"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","unstructured":"Tasaki M Yasui-Furukori N Yokoyama S et al. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep 2021b;41(3):379\u2013384; doi: 10.1002\/npr2.12190","DOI":"10.1002\/npr2.12190"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-34-1-247"},{"key":"e_1_3_4_31_1","first-page":"67","article-title":"Aripiprazole: An overview of a novel antipsychotic","volume":"17","author":"Uzun S","year":"2005","unstructured":"Uzun S, , Kozumplik O, , Mimica N, et al. Aripiprazole: An overview of a novel antipsychotic. Psychiatr Danub, 2005; 17(1\u20132):67\u201375.","journal-title":"Psychiatr Danub"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000175"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139717"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2022.0068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:31Z","timestamp":1777388191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2022.0068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1089\/cap.2022.0068"],"URL":"https:\/\/doi.org\/10.1089\/cap.2022.0068","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}